Bioactivity Signatures of Drugs vs. Environmental Chemicals Revealed by Tox21 High-Throughput Screening Assays.

Tox21 drug environmental chemical in vitro assay quantitative high throughput screening

Journal

Frontiers in big data
ISSN: 2624-909X
Titre abrégé: Front Big Data
Pays: Switzerland
ID NLM: 101770603

Informations de publication

Date de publication:
2019
Historique:
received: 29 05 2019
accepted: 29 11 2019
entrez: 11 3 2021
pubmed: 13 12 2019
medline: 13 12 2019
Statut: epublish

Résumé

Humans are exposed to tens of thousands of chemicals over the course of a lifetime, yet there remains inadequate data on the potential harmful effects of these substances on human health. Using quantitative high-throughput screening (qHTS), we can test these compounds for potential toxicity in a more efficient and cost-effective way compared to traditional animal studies. Tox21 has developed a library of ~10,000 chemicals (Tox21 10K) comprising one-third approved and investigational drugs and two-thirds environmental chemicals. In this study, the Tox21 10K was screened in a qHTS format against a panel of 70 cell-based assays with 213 readouts covering a broad range of biological pathways. Activity profiles were compared with chemical structure to assess their ability to differentiate drugs from environmental chemicals, and structure was found to be a better predictor of which chemicals are likely to be drugs. Drugs and environmental chemicals were further analyzed for diversity in structure and biological response space and showed distinguishable, but not distinct, responses in the Tox21 assays. Inclusion of other targets and pathways to further diversify the biological response space covered by these assays is likely required to better evaluate the safety profile of drugs and environmental chemicals to prioritize for in-depth toxicological studies.

Identifiants

pubmed: 33693373
doi: 10.3389/fdata.2019.00050
pmc: PMC7931954
doi:

Types de publication

Journal Article

Langues

eng

Pagination

50

Informations de copyright

Copyright © 2019 Ngan, Ye, Wu, Xia, Rossoshek, Simeonov and Huang.

Références

Sci Rep. 2014 Sep 26;4:6437
pubmed: 25257666
J Biomol Screen. 2015 Aug;20(7):887-97
pubmed: 25904095
Methods Mol Biol. 2016;1473:111-22
pubmed: 27518629
J Chem Inf Model. 2015 Mar 23;55(3):510-28
pubmed: 25647539
Environ Mol Mutagen. 2017 Aug;58(7):494-507
pubmed: 28714573
Int J Health Serv. 2016 Jul;46(3):523-30
pubmed: 27302930
Drug Discov Today. 2000 Feb;5(2):49-58
pubmed: 10652455
Environ Health Perspect. 2011 Aug;119(8):1142-8
pubmed: 21543282
Science. 2008 Feb 15;319(5865):906-7
pubmed: 18276874
Environ Health Perspect. 2015 Jan;123(1):49-56
pubmed: 25302578
Sci Rep. 2014 Jul 11;4:5664
pubmed: 25012808
Nucleic Acids Res. 2012 Jan;40(Database issue):D400-12
pubmed: 22140110
J Med Chem. 2008 Apr 24;51(8):2363-71
pubmed: 18363325
J Cheminform. 2017 Nov 28;9(1):61
pubmed: 29185060
PLoS One. 2017 May 22;12(5):e0177902
pubmed: 28531190
Sci Transl Med. 2011 Apr 27;3(80):80ps16
pubmed: 21525397
Ann Pharmacother. 2005 Jul-Aug;39(7-8):1260-4
pubmed: 15956239
Risk Anal. 2009 Apr;29(4):485-7; discussion 492-7
pubmed: 19076321
Drug Discov Today. 2013 Aug;18(15-16):716-23
pubmed: 23732176
Adv Ther. 2011 Oct;28(10):842-56
pubmed: 21894470
Sci Rep. 2018 Feb 28;8(1):3783
pubmed: 29491351
Drug Discov Today. 2010 Dec;15(23-24):997-1007
pubmed: 20708096
J Med Chem. 2010 Jan 14;53(1):37-51
pubmed: 19908840
Environ Health Perspect. 2013 Jul;121(7):756-65
pubmed: 23603828
Nat Commun. 2016 Jan 26;7:10425
pubmed: 26811972

Auteurs

Deborah K Ngan (DK)

Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, United States.

Lin Ye (L)

Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, United States.

Leihong Wu (L)

National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.

Menghang Xia (M)

Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, United States.

Anna Rossoshek (A)

Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, United States.

Anton Simeonov (A)

Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, United States.

Ruili Huang (R)

Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, United States.

Classifications MeSH